New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
08:30 EDTREGNRegeneron and Avalanche Biotechnologies sign development collaboration
Regeneron and Avalanche Biotechnologies announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The collaboration covers novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron. Avalanche will receive an upfront cash payment, contingent payments of up to $640M upon achievement of certain development and regulatory milestones, plus a royalty on worldwide net sales of collaboration products. The collaboration covers up to eight distinct therapeutic targets, and Regeneron will have exclusive worldwide rights for each product it moves forward in clinical development.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
06:43 EDTREGNRegeneron price target raised to $527 from $445 at Leerink
Subscribe for More Information
April 20, 2015
09:20 EDTREGNLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use